OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
10 2019
Historique:
received: 25 11 2018
revised: 29 07 2019
accepted: 04 08 2019
pubmed: 17 8 2019
medline: 7 11 2019
entrez: 17 8 2019
Statut: ppublish

Résumé

Our aim was to investigate the prevalence and potential risk factors for persistent and troublesome physical and psychological symptoms following treatment for ovarian cancer (OC). OvQuest is an international, internet-based, cross-sectional questionnaire which explored symptom burden and quality of life (QOL) after treatment for OC. Eligible women were aged 18 and over, diagnosed with OC at least 6 months previously and had received chemotherapy. Self-report data were collected including demographics, diagnosis and treatment, and standardised instruments for treatment-related toxicities, QOL, physical activity (PA) and supportive care needs. The survey included 1360 patients, of whom 421 (31%) had been treated for recurrent OC. 78% reported symptoms of peripheral neuropathy, 60% significant fatigue, 48% mood disturbance and 59% moderate-severe insomnia. Rates of fatigue, mood disorders, neuropathy and insomnia did not differ between women with or without recurrence. The majority of respondents were overweight or obese (high BMI, 59%) and 35% reported low PA. Low PA and high BMI were associated with poorer QOL scores and higher symptom burden across a range of domains. Women living after a diagnosis of OC report a substantial and ongoing symptom burden which impacts significantly on their quality of life across multiple domains. The reported associations between obesity, physical inactivity and poor QOL warrant prospective evaluation of lifestyle interventions to improve QOL.

Identifiants

pubmed: 31416612
pii: S0090-8258(19)31460-X
doi: 10.1016/j.ygyno.2019.08.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126-134

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Kate Webber (K)

Department of Oncology, Monash Health, and School of Clinical Sciences, Monash University, Melbourne, Australia; Prince of Wales Clinical School UNSW, and Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia. Electronic address: kate.webber@monash.edu.

Elisa Carolus (E)

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.

Linda Mileshkin (L)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Dirkje Sommeijer (D)

Department of Medical Oncology, Amsterdam UMC, Amsterdam, the Netherlands.

Jessica McAlpine (J)

University of British Columbia, Department of Gynecology and Obstetrics, Vancouver, Canada.

Sarah Bladgen (S)

University of Oxford, Department of Oncology, Oxford, UK.

Robert L Coleman (RL)

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX, United States.

Thomas J Herzog (TJ)

University of Cincinnati Cancer Institute, Dept. of Ob/Gyn, University of Cincinnati, United States.

Jalid Sehouli (J)

Medical University of Berlin, Charité Comprehensive Cancer Center (CCCC), Berlin, Germany.

Sara Nasser (S)

Medical University of Berlin, Charité Comprehensive Cancer Center (CCCC), Berlin, Germany.

Guelhan Inci (G)

Medical University of Berlin, Charité Comprehensive Cancer Center (CCCC), Berlin, Germany.

Michael Friedlander (M)

Prince of Wales Clinical School UNSW, and Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH